GCs and i.m. methylprednisolone remains at the discretion of the treating physician. In one clinical trial, i.m. methylprednisolone was applied at a dose of 120 mg every 3 weeks until week 9. At week 12, 100 mg were used and subsequently, injections were continued at monthly intervals and the dose was reduced by 20 mg every 12 weeks until week 48. Thereafter, the dose was reduced by 20 mg every 16 weeks until discontinuation The panel did not specify a clinical phenotype where i.m. GCs would be